Refers to an inhalable dry powder formulation, comprising Micronized particles of the compound 1 - (Cyclopropylmethoxy Difluoromethoxy - 3 - 4 - phenyl) - 2 - (3,5 - Dichloro - 1 - Oxy pyridin-4-yl) - acid ethyl ester (-) - 3 - (Cyclopropylmethoxy - 4 - metansulfonilamino as (-) - benzoic acid enantiomer and particles of a vehicle comprising a mixture of coarse particles comprising Alpha lactose Monohydrate have a diameter of 150 Mass 400 microns,Finely divided particles comprising Alpha lactose Monohydrate have an average diameter of Mass between 1 and 6 microns, and Magnesium Stearate which enantiomer (-) is present in an amount between 100 and 800 micrograms per Shot Inhaler, where also the fraction of Microparticles is composed of 90 to 99.5% by weight of between 0 and alpha lactose Monohydrate,5 and 10% by weight of Magnesium Stearate, and the relationship between the fraction of microparticles and the fraction of coarse particles is between 1: 99: 60% and 40% in weight. This formulation is an inhibitor of phosphodiesterase 4, being useful in the treatment of COPDSe refiere a una formulacion de polvo seco inhalable, que comprende particulas micronizadas del compuesto 1-(3-ciclopropilmetoxi-4-difluorometoxi-fenil)-2-(3,5-dicloro-1-oxi-piridin-4-il)-etil ester del acido (-)-3-ciclopropilmetoxi-4-metansulfonilamino-benzoico como enantiomero (-) y particulas de un vehiculo que comprende una mezcla de particulas gruesas que comprenden alfa-lactosa monohidrato que tienen un diametro de masa de 150 a 400 micrones, particulas finamente divididas que comprenden alfa-lactosa monohidrato que tienen un diametro medio de masa entre 1 y 6 micrones, y estearato de magnesio en donde dicho enantiomero (-) esta presente en una cantidad entre 100 y 800 microgramos por disparo de inhalador, en donde ademas la fraccion de microparticulas esta compuesto por 90 a 99,5% en peso de alfa-lactosa monohidrato y entre 0,5 y 10% en peso de estearato de magnesio, y la relacion entre la frac
